Cognition Therapeutics
$0.87
92
-$0.02-2.63% Thursday 20:00
Statistics
Day High
0.88
Day Low
0.82
52W High
3.83
52W Low
0.22
Volume
1,007,753
Avg. Volume
1,063,304
Mkt Cap
76.62M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
13MayExpected
Expected EPS
-0.09
Actual EPS
N/A
Financials
-Profit Margin
Unprofitable0Revenue
-67.94MNet Income
Analyst Ratings
$3.33Average Price Target
The highest estimate is 4.00.
From 3 ratings within the last 6 months. This is not an investment recommendation.
From 3 ratings within the last 6 months. This is not an investment recommendation.
Buy 100%
Hold 0%
Sell 0%
People Also Follow
This list is based on the watchlists of people on Stock Events who follow CGTX. It's not an investment recommendation.
Competitors
This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap22.63B
Lilly(Eli) &
LLY
Mkt Cap772.28B
Acadia Pharmaceuticals
ACAD
Mkt Cap3.83B
Anavex Life Sciences
AVXL
Mkt Cap684.57M
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Prothena
PRTA
Mkt Cap578.67M
Athira Pharma Inc
ATHA
Mkt Cap16.39M
AnaptysBio
ANAB
Mkt Cap1.02B
About
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Show more...
CEO
Ms. Lisa Ricciardi
Employees
25
Country
US
ISIN
US19243B1026
Listings
0 Comments
Share your thoughts
FAQ
What is Cognition Therapeutics stock price today?▼
The current price of CGTX is $0.87 USD — it has decreased by -2.63% in the past 24 hours. Watch Cognition Therapeutics stock price performance more closely on the chart.
What is Cognition Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cognition Therapeutics stocks are traded under the ticker CGTX.
Is Cognition Therapeutics stock price growing?▼
CGTX stock has risen by +18.89% compared to the previous week, the month change is a -16.54% fall, over the last year Cognition Therapeutics has showed a +145.06% increase.
What is Cognition Therapeutics market cap?▼
Today Cognition Therapeutics has the market capitalization of 76.62M
When is the next Cognition Therapeutics earnings date?▼
Cognition Therapeutics is going to release the next earnings report on May 13, 2026.
What were Cognition Therapeutics earnings last quarter?▼
CGTX earnings for the last quarter are -0.01 USD per share, whereas the estimation was -0.08 USD resulting in a +87.1% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Cognition Therapeutics revenue for the last year?▼
Cognition Therapeutics revenue for the last year amounts to 0 USD.
What is Cognition Therapeutics net income for the last year?▼
CGTX net income for the last year is -67.94M USD.
How many employees does Cognition Therapeutics have?▼
As of April 05, 2026, the company has 25 employees.
In which sector is Cognition Therapeutics located?▼
Cognition Therapeutics operates in the Health Care sector.
When did Cognition Therapeutics complete a stock split?▼
Cognition Therapeutics has not had any recent stock splits.
Where is Cognition Therapeutics headquartered?▼
Cognition Therapeutics is headquartered in Purchase, US.